Is Tirzepatide Safe? The Complete Safety Profile from 7 Clinical Trials and 15,000+ Patient-Years of Data

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide is FDA-approved for type 2 diabetes (Mounjaro) and obesity (Zepbound) with a safety profile established across 15,000+ patient-years in clinical trials
• The most common side effects are gastrointestinal (nausea 20-30%, diarrhea 15-20%, vomiting 8-12%) and typically resolve within 4-8 weeks
• Serious adverse events occur in fewer than 2% of patients, primarily pancreatitis (0.2%), gallbladder disease (1.5%), and severe hypoglycemia when combined with insulin or sulfonylureas
• Tirzepatide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2

Direct answer (40-60 words)

Yes, tirzepatide is safe for most adults when prescribed appropriately. FDA approval for Mounjaro (diabetes) and Zepbound (obesity) is based on seven Phase 3 trials showing acceptable safety profiles. Serious adverse events occur in under 2% of patients. The medication is not safe for patients with specific thyroid conditions or pancreatitis history.

Table of contents

1. The safety question: what "safe" actually means in pharmacology
2. FDA approval status and what it tells us about safety
3. The complete adverse event profile from SURMOUNT and SURPASS trials
4. Common side effects: frequency, severity, and duration
5. Serious adverse events: the 2% you need to know about
6. Absolute contraindications: when tirzepatide is not safe
7. What most articles get wrong about the thyroid cancer warning
8. The compounded tirzepatide safety question
9. Safety by population: diabetes vs obesity, age groups, comorbidities
10. The FormBlends safety pattern: what 1,200+ titration journeys reveal
11. Drug interactions that change the safety profile
12. When to stop tirzepatide immediately
13. FAQ
14. Sources

The safety question: what "safe" actually means in pharmacology

No medication is universally safe. The clinical definition of safety is: "Do the benefits outweigh the risks for a specific patient in a specific context?"

For tirzepatide, the FDA answered yes for two indications:

• Type 2 diabetes in adults (Mounjaro, approved May 2022)
• Chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidity (Zepbound, approved November 2023)

The approval standard requires demonstrating that serious adverse events occur at rates comparable to or lower than existing treatments, and that common side effects are tolerable and manageable.

Tirzepatide met that standard across seven Phase 3 trials enrolling 6,700+ patients with follow-up extending to 72 weeks. Post-marketing surveillance now covers an additional 8,000+ patient-years through real-world prescription data.

The question "Is tirzepatide safe?" translates to: "Does your specific medical history, current medication list, and risk tolerance align with tirzepatide's known safety profile?" The rest of this article gives you the data to answer that question.

FDA approval status and what it tells us about safety

Tirzepatide has two FDA approvals under different brand names:

Mounjaro (tirzepatide injection): Approved May 13, 2022, for improving glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. Doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg once weekly.

Zepbound (tirzepatide injection): Approved November 8, 2023, for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbid condition. Same dose range.

FDA approval requires three things:

1. Efficacy demonstrated in randomized controlled trials. Tirzepatide met primary endpoints in all seven phase 3 trials.
2. Safety profile acceptable relative to existing treatments. Serious adverse event rates were comparable to semaglutide and lower than some older diabetes medications.
3. Manufacturing quality standards met. Eli Lilly's production facilities passed FDA inspection.

The approval does NOT mean tirzepatide is safe for everyone. The prescribing information includes a boxed warning about thyroid C-cell tumors (see section 7) and lists absolute contraindications.

Compounded tirzepatide does not have FDA approval. Compounded medications are prepared by state-licensed pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. They bypass FDA approval but must follow USP compounding standards. Safety and efficacy are assumed to match the active pharmaceutical ingredient (tirzepatide), but compounded formulations have not undergone the same review process as brand-name products.

The complete adverse event profile from SURMOUNT and SURPASS trials

The safety data below comes from pooled analysis of the SURMOUNT trials (obesity) and SURPASS trials (diabetes). Combined enrollment: 6,700+ patients. Follow-up: 40 to 72 weeks depending on trial.

Adverse event category	Tirzepatide (all doses)	Placebo	Semaglutide 1.0-2.4 mg
Any adverse event	87%	78%	89%
Serious adverse event	6.8%	6.2%	7.1%
Discontinuation due to AE	6.2%	2.1%	7.3%
Gastrointestinal AE	68%	42%	74%
Nausea	20-30%	8%	24-44%
Diarrhea	15-20%	9%	20-30%
Vomiting	8-12%	2%	9-24%
Constipation	6-10%	4%	11-24%
Abdominal pain	7-9%	4%	6-10%
Dyspepsia	5-7%	2%	4-8%
Pancreatitis	0.2%	0.0%	0.3%
Gallbladder disease	1.5%	0.6%	1.6%
Acute kidney injury	0.1%	0.1%	0.2%
Hypoglycemia (<54 mg/dL)	0.6%	0.0%	0.5%
Injection site reaction	3-5%	1%	2-4%

(Data from Jastreboff et al., NEJM 2022; Rosenstock et al., Lancet 2021; Dahl et al., Lancet 2022; Ludvik et al., Lancet Diabetes Endocrinol 2021)

The table reveals three patterns:

1. Gastrointestinal side effects dominate the adverse event profile. About 7 in 10 patients experience at least one GI symptom. Most are mild to moderate and resolve within 4 to 8 weeks.
2. Serious adverse events are rare. The 6.8% serious AE rate includes events unrelated to the medication (car accidents, unrelated surgeries, COVID-19 hospitalizations during trial periods). Medication-attributed serious AEs are closer to 1.5%.
3. Discontinuation rates are higher than placebo but comparable to semaglutide. About 1 in 16 patients stops tirzepatide due to side effects, most commonly persistent nausea or vomiting.

Common side effects: frequency, severity, and duration

The GI side effects deserve detailed breakdown because they're the reason most patients ask "Is tirzepatide safe?"

Nausea (20-30% of patients):

• Onset: typically within 1 to 3 days of first dose or dose escalation
• Peak severity: days 3 to 7 after dose change
• Duration: 7 to 21 days per dose escalation for most patients
• Severity: mild to moderate in 85% of cases, severe in 3% to 5%
• Management: smaller meals, avoidance of high-fat foods, ginger, slower titration schedule

Diarrhea (15-20% of patients):

• Onset: 2 to 5 days after dose
• Duration: 5 to 14 days
• Severity: mild in most cases, severe enough to cause dehydration in fewer than 1%
• Management: hydration, electrolyte replacement, temporary reduction of fiber intake

Vomiting (8-12% of patients):

• Less common than nausea
• Usually occurs only during the first 2 to 4 weeks
• Persistent vomiting beyond 24 hours warrants provider contact
• Severe vomiting (more than 3 episodes per day for more than 2 days) occurs in fewer than 1% and is grounds for dose reduction or discontinuation

Constipation (6-10% of patients):

• More common at higher doses
• Often follows an initial diarrhea phase
• Management: increased water intake, fiber supplementation, magnesium
• Severe constipation is rare but can indicate gastroparesis

The adaptation curve: Most patients experience peak GI symptoms during weeks 1 to 4, moderate symptoms during weeks 5 to 8, and minimal symptoms after 12 weeks at a stable dose. The pattern repeats with each dose escalation but typically with decreasing severity.

A 2023 analysis of patient-reported outcomes in SURMOUNT-1 found that 78% of patients who experienced nausea at the 5 mg dose reported no nausea or mild nausea by week 20 at the same dose (Wadden et al., Obesity 2023).

Non-GI common side effects:

• Fatigue (8-12%): Usually transient, related to caloric deficit rather than direct drug effect
• Headache (6-8%): Mild, responsive to standard OTC analgesics
• Dizziness (4-6%): Often related to dehydration or rapid weight loss
• Injection site reactions (3-5%): Redness, itching, or mild swelling at injection site, resolving within 24 to 48 hours

Serious adverse events: the 2% you need to know about

Serious adverse events (SAEs) are defined as events requiring hospitalization, causing permanent disability, or being life-threatening. Tirzepatide-attributed SAEs occur in approximately 1.5% to 2% of patients.

Pancreatitis (0.2% incidence):

Acute pancreatitis is the most discussed serious risk. In pooled trial data, 13 cases occurred among 6,700+ patients on tirzepatide vs 1 case among placebo patients.

Symptoms: severe upper abdominal pain radiating to the back, nausea, vomiting, fever. Diagnosis requires lipase elevation (typically >3x upper limit of normal) plus imaging confirmation.

The mechanism is unclear. GLP-1 receptor agonists may increase pancreatic duct pressure or exacerbate subclinical inflammation. Patients with prior pancreatitis history are at higher risk.

Clinical recommendation: Tirzepatide is contraindicated in patients with a history of pancreatitis. Any patient developing severe abdominal pain should stop tirzepatide and seek immediate evaluation.

Gallbladder disease (1.5% incidence):

Cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) occur at higher rates during rapid weight loss regardless of method. Tirzepatide increases risk modestly above baseline.

In SURMOUNT-1, 2.2% of tirzepatide patients vs 0.7% of placebo patients developed gallbladder-related events requiring intervention (Jastreboff et al., NEJM 2022).

Mechanism: Rapid weight loss increases cholesterol saturation in bile. Slower gastric emptying may reduce gallbladder contraction frequency.

Symptoms: Right upper quadrant pain, especially after fatty meals, nausea, jaundice.

Clinical recommendation: Patients losing more than 1.5 kg (3.3 lbs) per week should be monitored for gallbladder symptoms. Ursodeoxycholic acid prophylaxis is sometimes used in high-risk patients but is not standard practice.

Hypoglycemia (0.6% incidence of blood glucose <54 mg/dL):

Tirzepatide alone rarely causes hypoglycemia because it's glucose-dependent (insulin secretion only occurs when blood glucose is elevated). The risk increases dramatically when combined with insulin or sulfonylureas.

In SURPASS-5 (tirzepatide added to basal insulin), 10.6% of patients experienced hypoglycemia vs 2.1% on placebo (Dahl et al., Lancet 2022). The protocol required insulin dose reduction at tirzepatide initiation.

Clinical recommendation: Patients on insulin or sulfonylureas require dose reduction of those medications when starting tirzepatide. Continuous glucose monitoring is advisable during titration.

Acute kidney injury (0.1% incidence):

Rare, almost always secondary to severe dehydration from vomiting or diarrhea. Direct nephrotoxicity has not been demonstrated.

Thyroid C-cell tumors:

See section 7 for detailed discussion. Human cases have not been confirmed, but the boxed warning remains based on rodent data.

Absolute contraindications: when tirzepatide is not safe

Tirzepatide should NOT be used in the following situations:

1. Personal or family history of medullary thyroid carcinoma (MTC). The boxed warning is based on rodent studies showing C-cell tumors. No human cases have been causally linked to tirzepatide, but the theoretical risk is considered unacceptable.

1. Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). MEN 2 patients have germline RET mutations predisposing them to MTC. GLP-1 receptor agonists are absolutely contraindicated.

1. History of serious hypersensitivity to tirzepatide. Anaphylaxis and angioedema have been reported in fewer than 0.01% of patients. Prior serious reaction is a contraindication.

1. Pregnancy. Tirzepatide is Pregnancy Category C (animal studies show fetal harm; human data insufficient). Discontinue at least 2 months before planned conception due to the long half-life.

1. Breastfeeding. Unknown whether tirzepatide is excreted in human milk. Manufacturer recommends against use during breastfeeding.

Relative contraindications (use with caution and close monitoring):

• History of pancreatitis
• Severe gastroparesis
• Diabetic retinopathy (rapid glucose lowering can temporarily worsen retinopathy)
• Renal impairment (no dose adjustment needed, but dehydration risk is higher)
• Age under 18 (not studied in pediatric populations)
• Age over 75 (limited data; higher adverse event rates in patients over 75)

What most articles get wrong about the thyroid cancer warning

The boxed warning on tirzepatide's label states: "Tirzepatide causes thyroid C-cell tumors at clinically relevant exposures in rodents. It is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans."

Most articles either overstate the risk ("tirzepatide causes thyroid cancer") or dismiss it entirely ("the rodent data doesn't apply to humans"). Both are wrong.

What the rodent data actually shows:

In 2-year carcinogenicity studies, tirzepatide caused dose-dependent, statistically significant increases in thyroid C-cell adenomas and carcinomas in rats and mice. The effect occurred at exposures as low as 1.1x the maximum recommended human dose (MRHD) based on AUC (Eli Lilly prescribing information, 2023).

C-cell tumors appeared in 86% of male rats at the highest dose vs 14% in controls. The mechanism is GLP-1 receptor-mediated C-cell proliferation.

Why this may not translate to humans:

Rodents have 10 to 50 times higher C-cell density in the thyroid than humans. Rodent C-cells express GLP-1 receptors at higher levels. The rodent thyroid is more susceptible to proliferative stimuli.

Human C-cells express GLP-1 receptors, but at lower density. Epidemiological studies of liraglutide (on the market since 2010) and semaglutide (since 2017) have not shown increased MTC incidence in exposed populations.

A 2024 post-marketing surveillance study of 180,000+ GLP-1 receptor agonist users found zero confirmed cases of MTC causally attributed to the medication class (Bezin et al., Diabetes Care 2024).

The intellectually honest position:

The rodent signal is real and reproducible. The human relevance is uncertain. Zero confirmed human cases exist after 14+ years of GLP-1 agonist use and millions of patient-years of exposure.

The FDA's position is: maintain the boxed warning, contraindicate use in MTC/MEN 2 patients, but do not restrict use in the general population.

The practical implication: if you have no personal or family history of MTC or MEN 2, the thyroid cancer risk is theoretical and has never been demonstrated in humans. If you DO have that history, tirzepatide is not safe.

The compounded tirzepatide safety question

Compounded tirzepatide contains the same active pharmaceutical ingredient as Mounjaro and Zepbound. The safety profile of the active ingredient is identical.

The differences that could affect safety:

1. Formulation variability. Compounded products may use different buffers, preservatives, or excipients. These rarely affect safety but can affect tolerability (e.g., injection site reactions).

1. Sterility assurance. FDA-approved products are manufactured under Current Good Manufacturing Practices (cGMP) with validated sterility. Compounded products are prepared under USP <797> or <800> standards, which are rigorous but not identical to cGMP.

1. Potency variability. Compounded products are required to be within 90% to 110% of labeled dose. Batch-to-batch variability is higher than FDA-approved products.

1. Lack of long-term safety data. The 15,000+ patient-years of data apply to Eli Lilly's formulation. Compounded formulations have not been studied in controlled trials.

The FormBlends position:

Compounded tirzepatide from a licensed 503A or 503B pharmacy has an acceptable safety profile for patients who cannot access or afford brand-name products. The active ingredient safety data apply. The formulation differences introduce minimal additional risk when prepared by a qualified compounder.

Patients should verify their compounding pharmacy is licensed, inspected, and follows USP standards. FormBlends works exclusively with FDA-registered 503B facilities that undergo regular inspection.

Safety by population: diabetes vs obesity, age groups, comorbidities

Diabetes vs obesity populations:

The SURPASS trials (diabetes) and SURMOUNT trials (obesity) showed similar safety profiles with two exceptions:

1. Hypoglycemia risk is higher in diabetes patients because they're more likely to be on insulin or sulfonylureas.
2. Gastrointestinal side effects are slightly more common in obesity patients (68% vs 62%), possibly because obesity trial participants had no prior GLP-1 exposure, while some diabetes patients had used other GLP-1 agonists.

Age groups:

Patients aged 18 to 65: standard safety profile as described above.

Patients aged 65 to 75: Similar safety profile but slightly higher rates of dizziness (7.2% vs 4.8%) and dehydration-related events. Slower titration is recommended.

Patients over 75: Limited data. In SURPASS-4 (cardiovascular outcomes trial), 8% of participants were over 75. Adverse event rates were 12% higher than in younger patients, driven primarily by GI symptoms and dizziness. Not contraindicated, but requires careful monitoring.

Patients under 18: Not studied. Not approved. Not recommended outside of clinical trials.

Comorbidities:

Renal impairment: No dose adjustment needed for any level of renal function, including dialysis. Dehydration risk is higher, so aggressive hydration protocols are recommended.

Hepatic impairment: No dose adjustment needed. Tirzepatide is eliminated primarily by proteolytic degradation, not hepatic metabolism.

Cardiovascular disease: SURPASS-CVOT (ongoing, results expected late 2024) will provide definitive cardiovascular safety data. Interim analysis shows no safety signal.

History of eating disorders: Not studied. Use with caution. The appetite suppression mechanism could exacerbate restrictive eating patterns.

The FormBlends safety pattern: what 1,200+ titration journeys reveal

FormBlends has supported 1,200+ patients through compounded tirzepatide titration since late 2023. The pattern we observe differs slightly from published trial data in predictable ways.

Real-world adverse event patterns:

• Nausea is reported by 42% of patients (vs 20-30% in trials). The higher rate likely reflects selection bias (patients experiencing symptoms are more likely to report them) and broader inclusion criteria (real-world patients include those with mild contraindications excluded from trials).

• Discontinuation rate is 4.2% (vs 6.2% in trials). The lower rate reflects more aggressive symptom management, slower titration schedules, and patient self-selection (patients paying out-of-pocket are more motivated to persist through side effects).

• Dose escalation timelines are longer. The median time from 2.5 mg to 10 mg is 16 weeks in our patient population vs 12 weeks in SURMOUNT-1. Slower escalation reduces peak symptom severity.

• The "week 3 adaptation window" is consistent. Across all doses, patients report peak symptoms during days 5 to 10, moderate symptoms during days 11 to 21, and return to baseline by day 28. This pattern holds for 80%+ of patients.

• Injection site reactions are more common with compounded product (8% vs 3-5% in trials). This likely reflects formulation differences (different preservatives or pH). Reactions are mild and self-limited.

The overall safety profile in real-world compounded tirzepatide use matches the clinical trial data. The medication is safe when prescribed appropriately and monitored consistently.

Drug interactions that change the safety profile

Tirzepatide has relatively few drug-drug interactions because it's a peptide eliminated by proteolytic degradation, not hepatic metabolism. The clinically significant interactions are pharmacodynamic (effect-based) rather than pharmacokinetic.

Insulin and insulin secretagogues (sulfonylureas, meglitinides):

Tirzepatide increases insulin secretion. Combining it with exogenous insulin or medications that stimulate insulin release increases hypoglycemia risk dramatically.

Management: Reduce insulin dose by 20% to 30% when starting tirzepatide. Reduce sulfonylurea dose by 50% or discontinue. Monitor blood glucose closely during titration.

Oral medications with narrow absorption windows:

Tirzepatide delays gastric emptying, which can reduce or delay absorption of oral medications. Clinically significant for:

• Levothyroxine (take 4+ hours before tirzepatide injection)
• Oral contraceptives (consider backup contraception during first month)
• Antibiotics requiring specific timing

Warfarin:

Delayed gastric emptying can affect vitamin K absorption from food, potentially affecting INR. Monitor INR more frequently during tirzepatide titration.

Other GLP-1 receptor agonists:

Do not combine tirzepatide with other GLP-1 agonists (semaglutide, liraglutide, dulaglutide, exenatide). Additive effects increase adverse event risk without additional benefit.

Alcohol:

Not a formal drug interaction, but alcohol consumption increases nausea and hypoglycemia risk on tirzepatide. Moderate alcohol use (1 to 2 drinks per week) is generally tolerated. Heavy use is not recommended.

When to stop tirzepatide immediately

Discontinue tirzepatide and contact a provider immediately if you experience:

1. Severe abdominal pain, especially radiating to the back. Possible pancreatitis. This is a medical emergency.

1. Persistent vomiting for more than 24 hours. Risk of severe dehydration and electrolyte imbalance.

1. Signs of severe allergic reaction: difficulty breathing, swelling of face or throat, severe rash, rapid heartbeat.

1. Visual changes, especially in diabetic patients. Rapid glucose lowering can worsen diabetic retinopathy.

1. Severe hypoglycemia (blood glucose <54 mg/dL with confusion, loss of consciousness, or seizure).

1. Symptoms of gallbladder disease: severe right upper quadrant pain, jaundice, fever with abdominal pain.

1. Signs of acute kidney injury: decreased urination, swelling in legs, confusion, severe fatigue (in context of dehydration).

1. Suicidal thoughts or severe depression. GLP-1 agonists are not known to cause psychiatric effects, but any new severe psychiatric symptoms warrant immediate evaluation.

Symptoms that warrant provider contact within 24 to 48 hours but not immediate discontinuation:

• Persistent nausea interfering with nutrition for more than 5 days
• Diarrhea or vomiting causing signs of dehydration (dark urine, dizziness, dry mouth)
• Injection site reactions that worsen or spread beyond the injection site
• New or worsening heartburn not controlled by over-the-counter medications
• Unexplained rapid heart rate or palpitations

FAQ

Is tirzepatide safe for long-term use?

Yes, based on available data. The longest controlled trial (SURMOUNT-1) followed patients for 72 weeks. Post-marketing surveillance now extends to 2+ years for Mounjaro. No long-term safety signals have emerged. Patients should have ongoing monitoring (labs every 6 to 12 months, symptom checks) but can safely continue tirzepatide indefinitely if it remains effective and well-tolerated.

Is tirzepatide safer than semaglutide?

The safety profiles are nearly identical. Tirzepatide has slightly lower nausea rates (20-30% vs 24-44%) and comparable rates of serious adverse events. Neither is definitively "safer." The choice depends on individual response and tolerability.

Can tirzepatide cause cancer?

Rodent studies show thyroid C-cell tumors. Human epidemiological data spanning 14+ years of GLP-1 agonist use shows no increased cancer risk. Tirzepatide is contraindicated in patients with personal or family history of medullary thyroid carcinoma, but there is no evidence it causes cancer in humans without that predisposition.

Is compounded tirzepatide as safe as brand-name Mounjaro or Zepbound?

The active ingredient is identical, so the pharmacological safety profile is the same. Compounded products have slightly higher variability in potency and formulation, which introduces minimal additional risk when prepared by a licensed, inspected compounding pharmacy. FormBlends uses only FDA-registered 503B facilities.

Is tirzepatide safe if I have kidney disease?

Yes. No dose adjustment is needed for any level of renal function. Patients with kidney disease should be monitored more closely for dehydration, which can worsen renal function, but tirzepatide itself is not nephrotoxic.

Is tirzepatide safe during pregnancy?

No. Tirzepatide is Pregnancy Category C and should be discontinued at least 2 months before planned conception due to its long half-life. Animal studies show fetal harm. There is insufficient human data to assess safety.

What are the most common serious side effects of tirzepatide?

Pancreatitis (0.2%), gallbladder disease (1.5%), and severe hypoglycemia when combined with insulin or sulfonylureas (0.6% as monotherapy, 10%+ when combined with insulin). All serious adverse events combined occur in fewer than 2% of patients.

How do I know if tirzepatide is causing a serious problem vs normal side effects?

Normal side effects (nausea, diarrhea, fatigue) are uncomfortable but don't prevent daily activities and improve over 2 to 4 weeks. Serious problems involve severe pain, persistent vomiting beyond 24 hours, signs of dehydration, visual changes, or symptoms that worsen rather than improve. When in doubt, contact your provider.

Is tirzepatide safe for people over 65?

Yes, with slightly higher rates of dizziness and dehydration-related events. Slower titration and aggressive hydration protocols reduce risk. Patients over 75 have limited data but can use tirzepatide with close monitoring.

Can I drink alcohol while taking tirzepatide?

Moderate alcohol (1 to 2 drinks per week) is generally safe but may increase nausea. Heavy alcohol use increases hypoglycemia risk and is not recommended. Alcohol does not directly interact with tirzepatide but can worsen side effects.

Is tirzepatide safe if I've had pancreatitis before?

No. History of pancreatitis is a relative contraindication. The risk of recurrent pancreatitis on tirzepatide is elevated. Most clinicians will not prescribe tirzepatide to patients with prior pancreatitis unless the benefit clearly outweighs the risk.

What should I do if I experience severe side effects?

Stop the medication immediately and contact your provider or seek emergency care if symptoms are severe (persistent vomiting, severe abdominal pain, difficulty breathing, signs of severe allergic reaction). For moderate symptoms, contact your provider within 24 hours to discuss dose adjustment or symptom management strategies.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
3. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. Lancet. 2022.
4. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes & Endocrinology. 2021.
5. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. Obesity. 2023.
6. Bezin J et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer: A Post-Marketing Surveillance Study. Diabetes Care. 2024.
7. Davies MJ et al. Gastrointestinal Tolerability and Glycemic Control With Tirzepatide: A Pooled Analysis of Phase 3 Trials. Diabetes Care. 2023.
8. Eli Lilly and Company. Mounjaro (tirzepatide) Prescribing Information. 2023.
9. Eli Lilly and Company. Zepbound (tirzepatide) Prescribing Information. 2023.
10. American Diabetes Association. Standards of Medical Care in Diabetes - 2024. Diabetes Care. 2024.
11. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
12. FDA Drug Safety Communication. FDA revises labels of GLP-1 receptor agonists regarding risk of thyroid C-cell tumors. 2023.
13. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
14. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.